Normophosphatemic familial tumoral calcinosis: description of a case with phosphate lowering therapy
Open Access
- 8 September 2026
- journal article
- case report
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (4) , 70-79
Abstract
Normophosphatemic familial tumoral calcinosis (NFTC) is characterized by cutaneous calcifications with no metabolic disorders; it manifests in the first years of life; associated with mutations in SAMD9 gene. Chronic trauma and transient hyperphosphatemia play a leading role in calcification formation. Surgical treatment can remove calcifications, but it does not prevent recurrence and can cause complications. Various conservative therapy is used. Lowering of blood phosphate levels is considered a promising pathogenetic treatment method. We present a clinical case of a patient with NFTC associated with the homozygous variant p.E1200K in SAMD9. A characteristic feature of our patient is the presence of multiple calcifications not only in the areas of injury (limbs), but also in areas of acne (face), as well as particularly active progression of the disease during puberty. A reduction in calcification size was observed after one year of continuous hypophosphatemic therapy (aluminum hydroxide and sevelamer 800 mg). The effectiveness of this therapy is debatable and limited by both poor patient tolerability of sevelamer and poor adherence. This is the first description of a patient with molecularly confirmed NFTC in Russia. A precise diagnosis allowed us to clarify the pathogenetic mechanism of calcification formation and propose treatment options.Keywords
This publication has 19 references indexed in Scilit:
- Successful treatment approaches for tumoral calcinosis in children and young people: A condition of diverse pathogenesisBone, 2024
- Alterations in SAMD9, AHSG, FRG2C, and FGFR4 Genes in a Case of Late-Onset Massive Tumoral CalcinosisAACE Clinical Case Reports, 2023
- Regression of calcinosis cutis after inkless tattoo in a patient with dermatomyositis: therapeutic potential of microneedlingOsteoporosis International, 2022
- Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfateJournal of Ultrasound, 2022
- Local, non-systemic, and minimally invasive therapies for calcinosis cutis: a systematic reviewArchives of Dermatological Research, 2021
- Beneficial Response to Phosphate Lowering Therapy in Normophosphatemic Tumoral CalcinosisIndian Pediatrics, 2021
- Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based reviewClinical Rheumatology, 2020
- Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patientsJournal of Endocrinological Investigation, 2019
- Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutationsAmerican Journal of Medical Genetics Part A, 2010
- Normophosphatemic Familial Tumoral Calcinosis Is Caused by Deleterious Mutations in SAMD9, Encoding a TNF-α Responsive ProteinJournal of Investigative Dermatology, 2008